Clinical breath analysis: discriminating between human endogenous compounds and exogenous (environmental) chemical confounders

Volatile organic compounds (VOCs) in exhaled breath originate from current or previous environmental exposures (exogenous compounds) and internal metabolic (anabolic and catabolic) production (endogenous compounds). The origins of certain VOCs in breath presumed to be endogenous have been proposed to be useful as preclinical biomarkers of various undiagnosed diseases including lung cancer, breast cancer, and cardio-pulmonary disease. The usual approach is to develop difference algorithms comparing VOC profiles from nominally healthy controls to cohorts of patients presenting with a documented disease, and then to apply the resulting rules to breath profiles of subjects with unknown disease status. This approach to diagnosis has a progression of sophistication; at the most rudimentary level, all measurable VOCs are included in the model. The next level corrects exhaled VOC concentrations for current inspired air concentrations. At the highest level, VOCs exhibiting discriminatory value also require a plausible biochemical pathway for their production before inclusion. Although these approaches have all shown some level of success, there is concern that pattern recognition is prone to error from environmental contamination and between-subject variance. In this paper, we explore the underlying assumptions for the interpretation and assignment of endogenous compounds with probative value for assessing changes. Specifically, we investigate the influence of previous exposures, elimination mechanisms and partitioning of exogenous compounds as confounders of true endogenous compounds. We provide specific examples based on a simple classical pharmacokinetic approach to identify potential misinterpretations of breath data and propose some remedies.

[1]  T. Nakajima,et al.  Dose-dependent metabolic interaction between benzene and toluene in vivo and in vitro. , 1979, Toxicology and applied pharmacology.

[2]  T. Risby Critical issues for breath analysis , 2008 .

[3]  Kevin Gleeson,et al.  Detection of lung cancer with volatile markers in the breath. , 2003, Chest.

[4]  K. B. Gross,et al.  Breath, urine, and blood measurements as biological exposure indices of short-term inhalation exposure to methanol , 1998, International archives of occupational and environmental health.

[5]  W. Miekisch,et al.  Breath gas aldehydes as biomarkers of lung cancer , 2009, International journal of cancer.

[6]  J. Beauchamp,et al.  Inhaled today, not gone tomorrow: pharmacokinetics and environmental exposure of volatiles in exhaled breath , 2011, Journal of breath research.

[7]  R. Cataneo,et al.  Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study , 1999, The Lancet.

[8]  W. Miekisch,et al.  Breath biomarkers for lung cancer detection and assessment of smoking related effects--confounding variables, influence of normalization and statistical algorithms. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[9]  Anton Amann,et al.  Methodological issues of sample collection and analysis of exhaled breath , 2010 .

[10]  R. Mukhopadhyay Don't waste your breath. Researchers are developing breath tests for diagnosing diseases, but how well do they work? , 2004, Analytical chemistry.

[11]  A. Jones,et al.  Variability of the blood/breath alcohol ratio in drinking drivers. , 1996, Journal of forensic sciences.

[12]  F. Bois,et al.  Toxicokinetics of inhaled trichloroethylene and tetrachloroethylene in humans at 1 ppm: empirical results and comparisons with previous studies. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[13]  M. Raizenne,et al.  Exhaled Ethanol and Acetaldehyde in Human Subjects Exposed to Low Levels of Ethanol , 2004, Inhalation toxicology.

[14]  L. Perbellini,et al.  Blood styrene concentrations in a “normal” population and in exposed workers 16 hours after the end of the workshift , 1993, International archives of occupational and environmental health.

[15]  J. Nunn,et al.  Components of the inspiratory-arterial isoflurane partial pressure difference. , 1993, British Journal of Anaesthesia.

[16]  L. Wallace,et al.  A linear model relating breath concentrations to environmental exposures: application to a chamber study of four volunteers exposed to volatile organic chemicals. , 1993, Journal of exposure analysis and environmental epidemiology.

[17]  R. Weiskopf,et al.  Comparison of Kinetics of Sevoflurane and Isoflurane in Humans , 1991, Anesthesia and analgesia.

[18]  J. Pleil Non Invasive Biomedical Analysis. Breath Networking Session at PittCon 2011, Atlanta, Georgia , 2011, Journal of breath research.

[19]  A. Modak Stable isotope breath tests in clinical medicine: a review , 2007, Journal of breath research.

[20]  Massimo Corradi,et al.  Determination of aldehydes in exhaled breath of patients with lung cancer by means of on-fiber-derivatisation SPME-GC/MS. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[21]  J. Pleil Breath Biomarkers Networking Sessions at PittCon 2010, Orlando, Florida , 2010, Journal of breath research.

[22]  M. Andersen,et al.  Refined PBPK model of aggregate exposure to methyl tertiary-butyl ether. , 2007, Toxicology letters.

[23]  E. J. Furtaw,et al.  An overview of human exposure modeling activities at the USEPA’s National Exposure Research Laboratory , 2001, Toxicology and industrial health.

[24]  J W Fisher,et al.  A human physiologically based pharmacokinetic model for trichloroethylene and its metabolites, trichloroacetic acid and free trichloroethanol. , 1998, Toxicology and applied pharmacology.

[25]  Joachim D Pleil,et al.  Role of Exhaled Breath Biomarkers in Environmental Health Science , 2008, Journal of toxicology and environmental health. Part B, Critical reviews.

[26]  M. Phillips,et al.  Metabolic and environmental origins of volatile organic compounds in breath. , 1994, Journal of clinical pathology.

[27]  L. Wallace,et al.  Recent advances in measuring exhaled breath and estimating exposure and body burden for volatile organic compounds (VOCs). , 1995, Environmental health perspectives.

[28]  P. Španěl,et al.  The challenge of breath analysis for clinical diagnosis and therapeutic monitoring. , 2007, The Analyst.

[29]  L. Wallace,et al.  Breath measurements as volatile organic compound biomarkers. , 1996 .

[30]  J D Pleil,et al.  Exhaled human breath measurement method for assessing exposure to halogenated volatile organic compounds. , 1997, Clinical chemistry.

[31]  J D Pleil,et al.  Sample Timing and Mathematical Considerations for Modeling Breath Elimination of Volatile Organic Compounds , 1998, Risk analysis : an official publication of the Society for Risk Analysis.

[32]  Bogusław Buszewski,et al.  Determination of volatile organic compounds in human breath for Helicobacter pylori detection by SPME-GC/MS. , 2011, Biomedical chromatography : BMC.

[33]  Philipp Lirk,et al.  Mass spectrometric profile of exhaled breath—field study by PTR-MS , 2005, Respiratory Physiology & Neurobiology.

[34]  J. Pleil,et al.  Trichloroethene levels in human blood and exhaled breath from controlled inhalation exposure. , 1998, Environmental health perspectives.

[35]  H J Clewell,et al.  The application of physiologically based pharmacokinetic modeling in human health risk assessment of hazardous substances. , 1995, Toxicology letters.

[36]  W. Miekisch,et al.  Diagnostic potential of breath analysis--focus on volatile organic compounds. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[37]  R. Weiskopf,et al.  Kinetics of desflurane, isoflurane, and halothane in humans. , 1991, Anesthesiology.

[38]  H. Haick,et al.  Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors , 2010, British Journal of Cancer.

[39]  S M Rappaport,et al.  Exposure reconstruction for reducing uncertainty in risk assessment: example using MTBE biomarkers and a simple pharmacokinetic model , 2007, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[40]  W. Cao,et al.  Breath analysis: potential for clinical diagnosis and exposure assessment. , 2006, Clinical chemistry.

[41]  L. Perbellini,et al.  Biological monitoring of occupational exposure to N,N-dimethylacetamide with identification of a new metabolite , 2003, Occupational and environmental medicine.

[42]  Niki Fens,et al.  Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma. , 2009, American journal of respiratory and critical care medicine.

[43]  V. Shestivska,et al.  Variability in the concentrations of volatile metabolites emitted by genotypically different strains of Pseudomonas aeruginosa , 2012, Journal of applied microbiology.

[44]  G Maranelli,et al.  Partition coefficients of some industrial aliphatic hydrocarbons (C5-C7) in blood and human tissues. , 1985, British journal of industrial medicine.

[45]  Royston Goodacre,et al.  Non-invasive Metabolomic Analysis of Breath Using Differential Mobility Spectrometry in Patients with Chronic Obstructive Pulmonary Disease and Healthy Smokers , 2022 .

[46]  L. Perbellini,et al.  Comparison of breath, blood and urine concentrations in the biomonitoring of environmental exposure to 1,3-butadiene, 2,5-dimethylfuran, and benzene , 2003, International archives of occupational and environmental health.

[47]  William J Tyler,et al.  A quantitative overview of biophysical forces impinging on neural function , 2013, Physical biology.

[48]  David Smith,et al.  Progress in SIFT-MS: breath analysis and other applications. , 2011, Mass spectrometry reviews.

[49]  T. Risby,et al.  Clinical application of breath biomarkers of oxidative stress status. , 1999, Free radical biology & medicine.

[50]  K. Korach,et al.  Alterations in estrogen levels during development affects the skeleton: use of an animal model. , 1995, Environmental health perspectives.

[51]  Bogusław Buszewski,et al.  Human exhaled air analytics: biomarkers of diseases. , 2007, Biomedical chromatography : BMC.

[52]  C. Weisel,et al.  Human respiratory uptake of chloroform and haloketones during showering , 2005, Journal of Exposure Analysis and Environmental Epidemiology.

[53]  W. Nelson,et al.  Uptake and decay of volatile organic compounds at environmental concentrations: application of a four-compartment model to a chamber study of five human subjects. , 1997, Journal of Exposure Analysis and Environmental Epidemiology.

[54]  Harvey J Clewell,et al.  Use of a Physiologically Based Pharmacokinetic Model to Identify Exposures Consistent With Human Biomonitoring Data for Chloroform , 2006, Journal of toxicology and environmental health. Part A.